bretylium tosylate- bretylium tosylate injection
pharmaceutics international, inc. (pii) - bretylium tosylate (unii: 78zp3yr353) (bretylium - unii:rzr75eq2kj) - bretylium tosylate injection, usp is indicated in the prophylaxis and therapy of ventricular fibrillation. bretylium tosylate injection, usp is also indicated in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine. use of bretylium tosylate injection, usp should be limited to intensive care units, coronary care units or other facilities where equipment and personnel for constant monitoring of cardiac arrhythmias and blood pressure are available. following injection of bretylium tosylate there may be a delay of 20 minutes to 2 hours in the onset of antiarrhythmic action, although it appears to act within minutes in ventricular fibrillation. the delay in effect appears to be longer after intramuscular than after intravenous injection. there are no contraindications to use in treatment of ventricular fibrillation or life-threatening refractory ventricular arrhythmias, excep
bretylium tosylate injection
ani pharmaceuticals, inc. - bretylium tosylate (unii: 78zp3yr353) (bretylium - unii:rzr75eq2kj) - bretylium tosylate injection, usp is indicated in the prophylaxis and therapy of ventricular fibrillation. bretylium tosylate injection, usp is also indicated in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine. use of bretylium tosylate injection, usp should be limited to intensive care units, coronary care units or other facilities where equipment and personnel for constant monitoring of cardiac arrhythmias and blood pressure are available. following injection of bretylium tosylate there may be a delay of 20 minutes to 2 hours in the onset of antiarrhythmic action, although it appears to act within minutes in ventricular fibrillation. the delay in effect appears to be longer after intramuscular than after intravenous injection. there are no contraindications to use in treatment of ventricular fibrillation or life-threatening refractory ventricular arrhythmias, excep
bretylium tosylate injection usp solution
sandoz canada incorporated - bretylium tosylate - solution - 50mg - bretylium tosylate 50mg - class iii antiarrythmics
bretylium tosylate 0.4% and dextrose 5% inj solution
abbott laboratories, limited - bretylium tosylate; dextrose - solution - 4mg; 50mg - bretylium tosylate 4mg; dextrose 50mg - class iii antiarrythmics
bretylium tosylate 0.2% and dextrose 5% inj solution
abbott laboratories, limited - bretylium tosylate; dextrose - solution - 2mg; 50mg - bretylium tosylate 2mg; dextrose 50mg - class iii antiarrythmics
bretylium tosylate inj 50mg/ml solution
abbott laboratories, limited - bretylium tosylate - solution - 50mg - bretylium tosylate 50mg - class iii antiarrythmics
bretylium tosylate
abbott laboratories (nz) ltd - bretylium tosilate 50 mg/ml - solution for injection - 50 mg/ml - active: bretylium tosilate 50 mg/ml excipient: hydrochloric acid sodium hydroxide water for injection
bretylate inj 50mg/ml liquid
glaxo wellcome inc. - bretylium tosylate - liquid - 50mg - bretylium tosylate 50mg - class iii antiarrythmics
bretylium tosilate 500mg/10ml solution for injection minijet pre-filled syringes
celltech pharma europe ltd - bretylium tosilate - solution for injection - 50mg/1ml
bretylol
boots healthcare new zealand limited - bretylium tosilate 50 mg/ml; - solution for injection - 500mg/10ml - active: bretylium tosilate 50 mg/ml